• Angelo Santamaria, Antonino Di Benedetto, Elisabetta Petrella, Basilio Pintaudi, Francesco Corrado, Rosario D'Anna, Isabella Neri, and Fabio Facchinetti.
• a Department of Pediatrics , Gynecology, Microbiology and Biomedical Sciences, University of Messina , Messina , Italy .
• J. Matern. Fetal. Neonatal. Med. 2016 Oct 1; 29 (19): 3234-7.

ObjectiveTo evaluate whether myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) rate in overweight women.MethodsIn an open-label, randomized trial, myo-inositol (2 g plus 200 μg folic acid twice a day) or placebo (200 μg folic acid twice a day) was administered from the first trimester to delivery in pregnant overweight non-obese women (pre-pregnancy body mass index ≥ 25 and < 30 kg/m(2)). The primary outcome was the incidence of GDM.ResultsFrom January 2012 to December 2014, 220 pregnant women were randomized at two Italian University hospitals, 110 to myo-inositol and 110 to placebo. The incidence of GDM was significantly lower in the myo-inositol group compared to the placebo group (11.6% versus 27.4%, respectively, p = 0.004). Myo-inositol treatment was associated with a 67% risk reduction of developing GDM (OR 0.33; 95% CI 0.15-0.70).ConclusionsMyo-inositol supplementation, administered since early pregnancy, reduces GDM incidence in overweight non-obese women.

20 keywords...

hide…